Chemotherapy and Radiotherapy for Osteolymphoma
- Conditions
- Osteolymphoma
- Interventions
- Drug: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.Radiation: Radiotherapy
- Registration Number
- NCT00141648
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Brief Summary
This trial is intended to determine the results obtained when standard treatment for Non Hodgkin's lymphoma is applied to the disease in a rare subtype which arises in bone. Patients in the study undergo a detailed assessment, then treatment with chemotherapy and radiotherapy, followed by close monitoring.
- Detailed Description
Patients with non-Hodgkin's lymphoma arising primarily in bone have been studied using a number of different names making literature searching difficult. The term Osteolymphoma has been proposed to make searching easier in the future. Patients in this study undergoing staging which includes isotope bone scanning and PET scanning where available. Eligible patients then undergo treatment with three cycles of CHOP chemotherapy at conventional doses and shrinking field radiotherapy to a total of 45 Gy. Monoclonal antibodies are not included as good results have been obtained without using them. After treatment the patients are regularly monitored. The trial is presented twice per year at the meetings of TROG, ALLG and AROLG.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 70
- Histologically confirmed non-Hodgkin's lymphoma in a bony site
- Limited extraosseous disease
- Ann Arbor stage IE
- Age >17
- ECOG performance status <3
- Expected survival > 6 months
- Patients capable of childbearing are using adequate contraception.
- Written informed consent
- Previous radiotherapy
- Previous malignancy
- Medically unfit to undergo treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Radiotherapy Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle. 1 Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone. Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
- Primary Outcome Measures
Name Time Method Overall Survival. The time from registration to the date of death Main analysis when accrual is complete at approx. 10 years.
- Secondary Outcome Measures
Name Time Method Time to local or regional failure. Measured from registration. Main analysis when accrual is complete at approx. 10 years. Pathological fracture rate. Measured from registration. Main analysis when accrual is complete at approx. 10 years.
Trial Locations
- Locations (20)
Peter MacCallum Cancer Centre
🇦🇺East Melbourne, Victoria, Australia
Andrew Love Cancer Care Centre, Geelong Hospital
🇦🇺Geelong, Victoria, Australia
Launceston General Hospital
🇦🇺Launceston, Tasmania, Australia
Royal Hobart Hospital
🇦🇺Hobart, Tasmania, Australia
Royal Prince Alfred Hospital
🇦🇺Camperdown, New South Wales, Australia
Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
Royal Brisbane Hospital
🇦🇺Herston, Queensland, Australia
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Westmead Hospital
🇦🇺Wentworthville, New South Wales, Australia
North Queensland Oncology Service
🇦🇺Townsville, Queensland, Australia
The Wesley Radiation Oncology Pty Ltd
🇦🇺Auchenflower, Queensland, Australia
Wollongong Hospital
🇦🇺Wollongong, New South Wales, Australia
Calvary Mater Newcastle
🇦🇺Newcastle, New South Wales, Australia
Mater QRI
🇦🇺South Brisbane, Queensland, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
East Coast Cancer Centre, John Flynn Hospital
🇦🇺Tugun, Queensland, Australia
Auckland Hospital
🇳🇿Auckland, New Zealand
Sir Charles Gairdner Hospital
🇦🇺Nedlands, Western Australia, Australia
Waikato Hospital
🇳🇿Hamilton, New Zealand
Palmerston North Hospital
🇳🇿Palmerston North, New Zealand